European Journal of Clinical Investigation · 2025 · 12 citations · 105 references
MedicineCardiologyImmunologyImmunoregulationInflammationPreventive CardiologyCardiovascular DiseaseCardiovascular Disease PreventionCoronary Artery DiseaseIschemic Heart DiseaseAtherosclerosis Molecular MechanismsInterleukin-6 Mediated RegulationPro-inflammatory Cytokine CascadesPro-inflammatory Cytokine ExpressionVascular Endothelial Dysfunction
BACKGROUND: Interleukin-6 (IL-6), a pro-inflammatory cytokine and anti-inflammatory myokine, is involved in immune regulation and metabolic control. Persistent IL-6 activation, particularly via trans-signalling, is implicated in endothelial dysfunction, atherosclerosis, myocardial fibrosis, and adverse remodelling. METHODS: This review summarizes experimental, genetic, and clinical evidence on the role of IL-6 in cardiovascular disease (CVD), focusing on the molecular pathways, prognostic value, and its potential as a therapeutic target. Experimental and genome-wide association studies, as well as clinical trials-including IL-6-targeted interventions-are comprehensively reviewed. RESULTS: While acute activation of IL-6/STAT signalling, that is, before or during myocardial infarction, is protective, chronic activation leads to maladaptive changes in the myocardium. Mechanistically, IL-6 promotes vascular inflammation, monocyte recruitment, coagulation, and fibrosis. Mendelian randomization implies a causal role of IL-6 signalling in coronary artery disease, stroke, and atrial fibrillation. Simultaneously, elevated IL-6 levels predict adverse outcomes in acute coronary syndromes and heart failure. Pharmacological IL-6 inhibition reduces systemic inflammation, with pilot data implying acceptable safety profiles. Large phase III outcome trials are ongoing, shedding light on the impact of IL-6 blockade in high-risk populations, such as those with chronic kidney disease and heart failure with preserved or mildly reduced ejection fraction. CONCLUSIONS: IL-6 plays a dual role-protective versus pathogenic and acute versus chronic. Chronic IL-6 links inflammation and metabolic dysregulation to structural cardiovascular damage. Chronic IL-6 activation requires therapeutic approaches tailored to disease context, timing and signalling mode. The results of ongoing trials will clarify whether IL-6-targeted interventions can be integrated into cardiovascular prevention and management strategies, complementing established therapies and addressing residual inflammatory risk.
105
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Paul M. Ridker, Tom Thurén, Jean MacFadyen et al. · New England Journal of Medicine · 2017 · 9.1K citations · Full text
Molecular cloning and expression of an IL-6 signal transducer, gp130
Masahiko Hibi, Masaaki Murakami, Mikiyoshi Saito et al. · Cell · 1990 · 1.3K citations
Low-Dose Methotrexate for the Prevention of Atherosclerotic Events
Paul M. Ridker, Brendan M. Everett, Aruna D. Pradhan et al. · New England Journal of Medicine · 2018 · 1.3K citations · Full text
Interleukin-6-deficient mice develop mature-onset obesity
Ville Wallenius, Kristina Wallenius, Bo Åhrén et al. · Nature Medicine · 2002 · 1.2K citations